文献速递血栓与止血

生长分化因子-15预测癌症患者出血

Growth differentiation factor-15 for prediction of bleeding in cancer patients.
PubMed 文献 · J Thromb Haemost · 2021-11-02

基于AVERT试验中574例接受预防性阿哌沙班或安慰剂治疗的癌症患者,评估血浆GDF-15对出血事件的预测价值。在阿哌沙班治疗组中,GDF-15预测大出血的AUC为0.73,最高三分位(≥2607 ng/L)较大出血风险显著高于最低三分位(<1470 ng/L),校正后HR为2.80。GDF-15也与临床相关非大出血和任何出血显著相关。

要点

  • GDF-15最高三分位(≥2607 ng/L)与癌症患者大出血风险独立相关,校正后HR 2.80。
  • GDF-15对临床相关非大出血和任何出血也有显著预测价值,校正后HR分别为1.67和2.12。
  • 该研究为假设生成性,首次提示GDF-15可用于癌症血栓预防患者的出血风险分层。

核心结论

  • GDF-15可预测接受血栓预防治疗的癌症患者发生大出血、临床相关非大出血及任何出血的风险。

研究设计与样本

  • 研究基于AVERT试验,纳入574例随机接受预防性阿哌沙班或安慰剂的癌症患者,随访180天。
  • 血浆GDF-15浓度采用Elecsys GDF-15商业检测试剂盒(Roche Diagnostics GmbH)集中测定。

主要发现

  • 在阿哌沙班治疗组中,GDF-15预测大出血的ROC曲线下面积为0.73(95%CI 0.44-1.00)。
  • 与最低三分位(<1470 ng/L)相比,最高三分位(≥2607 ng/L)的大出血风险显著增高(HR 3.19;95%CI 2.41-4.22)。
  • 校正性别、年龄、抗血小板药物使用和胃肠道癌症后,最高三分位的大出血风险仍显著增高(校正HR 2.80;95%CI 1.91-4.11)。
  • GDF-15与临床相关非大出血显著相关(校正HR 1.67;95%CI 1.08-2.58),与任何出血也显著相关(校正HR 2.12;95%CI 1.38-3.25)。

关键数值与推荐

  • GDF-15最低三分位定义为<1470 ng/L,最高三分位定义为≥2607 ng/L。
  • 大出血风险比较的参照组为最低三分位(<1470 ng/L)。
  • 临床相关非大出血和任何出血的关联报告为校正后HR值。

临床怎么用

  • 对于考虑初级血栓预防的癌症患者,可检测血浆GDF-15以辅助评估出血风险。
  • GDF-15水平≥2607 ng/L提示大出血风险显著增高,应加强出血监测。

局限性

  • 研究结论为假设生成性,需进一步验证。
  • GDF-15预测大出血的AUC置信区间较宽(0.44-1.00),提示估计不确定性较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growth differentiation factor-15 (GDF-15) is a strong predictor for bleeding in patients with atrial fibrillation, but there are no data on cardiovascular outcomes for this biomarker in cancer patients. Bleeding risk assessment is important in cancer patients when considering primary thromboprophylaxis because it is associated with an increased bleeding risk. OBJECTIVES: To evaluate GDF-15 as predictor for bleeding events in cancer patients previously enrolled in the AVERT trial. PATIENTS/METHODS: In this trial, 574 participants were randomized to prophylactic apixaban or placebo and followed for 180 days for venous thromboembolism, major bleeding, clinically relevant nonmajor bleeding, and any bleeding. Plasma concentrations of GDF-15 were measured centrally with the Elecsys GDF-15 commercial assay kit (Roche Diagnostics GmbH). RESULTS: In apixaban recipients, the area under the receiver operator characteristic curve of GDF-15 for major bleeding was 0.73 (95% confidence interval [CI], 0.44-1.00). Compared with the lowest GDF-15 tertile (<1470 ng/L), major bleeding risk was significantly higher in the highest tertile (≥2607 ng/L; hazard ratio [HR] 3.19; 95% CI, 2.41-4.22), also when adjusting for sex, age, antiplatelet use, and gastrointestinal cancer (adjusted HR 2.80; 95% CI, 1.91-4.11). GDF-15 was also significantly associated with clinically relevant nonmajor bleeding (adjusted HR 1.67; 95% CI, 1.08-2.58) and any bleeding (adjusted HR 2.12; 95% CI, 1.38-3.25). CONCLUSIONS: Although hypothesis generating, this is the first study to show that GDF-15 predicts bleeding in cancer patients receiving thromboprophylaxis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mulder FI, Bosch FTM, Carrier M, et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost. 2021. PMID: 34662498. doi:10.1111/jth.15559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。